Multigene testing in localized prostate cancer

Ashley E. Ross

Research output: Contribution to journalArticle

Abstract

Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.

Original languageEnglish (US)
Pages (from-to)659-662
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multigene testing in localized prostate cancer'. Together they form a unique fingerprint.

  • Cite this